

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100776-PIP01-22-M01

### **Scope of the Application**

#### **Active Substance(s)**

Nemolizumab

#### **Condition(s)**

Treatment of atopic dermatitis.

#### **Pharmaceutical Form(s)**

Powder for solution for injection

#### **Route(s) of Administration**

SUBCUTANEOUS USE

#### **Name / Corporate name of the PIP applicant**

Galderma (UK) Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Galderma (UK) Limited submitted to the licensing authority on 25/11/2022 12:16 GMT an application for a Modification

The procedure started on 04/05/2023 13:06 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100776-PIP01-22-M01

Of 31/05/2023 10:31 BST

On the adopted decision for Nemolizumab (MHRA-100776-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a deferral included in that paediatric investigation plan).

This decision applies to a Modification for Nemolizumab, Powder for solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Galderma (UK) Limited, Evergreen House North, London, UNITED KINGDOM, NW1 2DX

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of atopic dermatitis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age. Pharmaceutical form(s): Powder for solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of atopic dermatitis

## 2.2 Indication(s) targeted by the PIP:

Treatment of moderate to severe atopic dermatitis not adequately controlled with topical treatments.

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age.

## 2.4 Pharmaceutical Form(s):

Powder for solution for injection

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of age-appropriate pharmaceutical form
Non-Clinical Studies	1	Study 2 Study to evaluate the effects on pre-and postnatal development in cynomolgus monkeys and to assess the systemic exposure in dams and offspring along with milk concentrations.
Clinical Studies	7	Study 3 (SPR.118161) Placebo-controlled, randomised, multicentre, study to evaluate efficacy and safety of nemolizumab. Study 4 (SPR.118169) Placebo-controlled, randomised, multicentre, study to evaluate efficacy and safety of nemolizumab. Study 5 (SPR.118163) Single arm, open-label, long-term study to evaluate efficacy and safety of nemolizumab. Study 6 Deleted during procedure MHRA-100776-PIP01-22-M01. Study 7 Deleted during procedure MHRA-100776-PIP01-22-M01. Study 8 Deleted during procedure MHRA-100776-PIP01-22-M01. Study 9 Deleted during procedure MHRA-100776-PIP01-22-M01. Study 11 (SPR.116912) Added during procedure MHRA-100776-PIP01-22-M01. Single-arm, open-

		label study to evaluate PK, safety and activity of nemolizumab in adolescents with moderate to severe atopic dermatitis (AD). Study 12 (SPR.118126) Added during procedure MHRA-100776-PIP01-22-M01. Single-arm, open-label trial to evaluate pharmacokinetics (PK), safety and activity of nemolizumab in children from 2 years to less than 12 years with moderate to severe atopic dermatitis. Study 13 (SPR.204784) Added during procedure MHRA-100776-PIP01-22-M01. Double-blind, randomised, placebo-controlled trial to evaluate efficacy and safety of nemolizumab in children from 2 years to less than 12 years with moderate to severe atopic dermatitis. Study 14 (SPR.205513) Added during procedure MHRA-100776-PIP01-22-M01. Open-label, long-term, extension trial to evaluate safety and activity of nemolizumab in children from 2 years to less than 12 years with moderate to severe atopic dermatitis.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	1	Study 10 1-compartment model with 1st order absorption (PK).
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	30/06/2028
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes

